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Abstract
Molecular target therapy is a recently rapid progress in the management of 
hematological malignancies. In myeloid neoplasm, the sensational response to 
treatment and the overall survival and quality of life improvement for treat-
ment with tyrosine kinase inhibitors (TKI) agents for patients with chronic 
myeloid leukemia and the introduction of Janus kinase (JAK)-2 inhibitors 
(ruxolitinib) may offer comparative advantage in myeloproliferative diseases of 
patients with polycythemia vera (PV), primary myelofibrosis (MF) and essential 
thrombocythemia (ET). The introduction of all-trans-retinoic acid (ATRA) and 
mylotarg for acute myeloid leukemia patients, have had major impacts on the 
treatment protocol plan and different other targeted therapeutic highly effec-
tive agents, including FLT3, histone deacetylase inhibitors and farnesyl trans-
ferase. In malignant lymphomas and lymphatic leukemia the feature has been 
the presentation of rituximab, with critical enhancements within the treatment 
of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. The most 
recent 15 years has encountered a rapidly broadening interest and acknowledg-
ment that leukemic stem cells, including an enhanced capacity to target them, 
may hold the way to enhanced reaction and diminished relapse rates over both 
lymphoid and myeloid disorders. Technical regulation for growing new person-
alized anticancer target therapy agents have changed and presently evaluated 
and screened.
Keywords: target therapy, hematological malignancy, leukemia, lymphoma, 
myeloma
1. Introduction
The past few a long time have seen gigantic changes within inside the approach 
to making advanced anticancer therapy, in one side due to advanced unused 
innovations and computer instruments, and on other side due to other ways of 
inquire about centered on progressing our understanding about the fundamental of 
molecular pathways and genetic changes that driving the advancement of cancer, 
discoveries which are making a difference us to superior distinguish which patients 
will advantage from the plan focused on treatment and permit the researcher to 
personalized target therapy guidelines. This ever-growing information base has 
too driven to the distinguishing proof of more molecular targets and the ensuing 
development of new focused on target therapy agents that will shaping treatment of 
cancer in the future [1].
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Personalized targeted therapy is a drug that squares the cancer cells development 
by interfering with particular molecule needed for carcinogenesis and growth of 
tumors [2] instead of essentially interfering with quickly isolating dividing cells. The 
personalized target therapy for cancer diseases has been a noteworthy stimulus for the 
advancing field of pharmacogenomics. Moreover it is characterized as pharmacoge-
nomics can envelop germline and significant (infection) gene and protein estimations 
utilized to expect the probability that a patient’s tumor will react to an explicit single-
agent or multiagent chemotherapy protocols and the chance of hurtful side effects [3]. 
Besides the US Food and Drug Administration (FDA) has considered target treatment 
as a personalized therapy approved and named with a specific reference to at the same 
time or as of now asserted illustrative test that must be performed some time recently 
the persistent can be considered qualified to get the target therapy agents [4].
Personalized targeted therapy begun modern transformation approximately the 
improvement of cancer treatment to a person patient’s tumor, the financial matters 
of cancer care around the world. As expanded of analyzed patients with cancer and 
as these patients live longer, essential care clinics will make strides wellbeing care 
for patients who have gotten cancer target therapy [5, 6].
2. Development of target therapy
The outcome after revolution of target therapy was improved in lymphoma, 
myeloma and chronic leukemia. Imatinib as first generation of TKI has had an excel-
lent outcome on chronic myeloid leukemia, bortezomib and rituximab, which has 
also high percentage of remission in myeloma and lymphoma, respectively [7, 8].  
In patients with multiple myeloma preclinical studies have informed the rational 
use of combination therapies, such as bortezomib with lenalidomide to trigger both 
intrinsic and extrinsic apoptotic signaling [9].
Chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL) and 
idiopathic myelofibrosis (IM) fundamentally influence elderly patients, numer-
ous of whom have therapeutic comorbidities that constrain the utilize of standard 
chemotherapy. Treatment with target therapy such as imatinib and rituximab are 
frequently less harmful and superior endured than conventional chemotherapy, 
advertising these patients extra treatment choices [10].
3. Acute myeloid leukemia (AML)
The targeted therapy for patients with AML in recent years maybe most out-
standing within the molecularly targeted therapy against its specific genetic abnor-
mality of acute promyelocytic leukemia (APL). The initial (induction) treatment of 
APL with all-trans-retinoic acid (ATRA) play role in cells differentiation in patients 
with APL with t(15;17)(q22;q21) and has driven to disease-free survival and/or cure 
in 75% of patients with APL [11].
The introduction of ATRA in patients works to differentiation blast of acute 
promyelocytic leukemia (APL) to AML blast. The retinoic acid disorder is the most 
common complication characterized by fever, disseminated intravascular coagula-
tion and cardiac, respiratory and renal function disorders. These disorders, which 
are seen in some patients, particularly patients associated with leukocytosis, can be 
treated or improved with chemotherapy or corticosteroids.
The current standard treatment of APL in induction and consolidation, include 
introduction of ATRA simultaneously with cytarabine and anthracycline and 
pursued by maintenance in combination with low-dose chemotherapy [12, 13].
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Moreover, in an endeavor to maintain a strategic distance from routine che-
motherapy, the addition of ATRA in combination with gemtuzumab ozogamicin 
has been utilized as induction with achievement of remissions (Table 1) [14]. 
Gemtuzumab ozogamicin (GO; Mylotarg) is a selective anti CD33 anti-body 
conjugated with calicheamicin facilitated against CD33 surface marker and com-
municated by more than 90% of myeloid leukemic blasts and is harmful to DNA 
calicheamicin. The overall response (OR) rate reported in 30% patients with AML 
and CD33+ treated with GO.
The rate of myelosuppression as common side effects of chemotherapy, was less 
with GO, in spite of the fact that acute respiratory distress syndrome and pulmonary 
edema have been experienced in patients with leukocytosis but less than 30,000/mL 
[15]. In May 2000, FDA have approved “GO” for patients above 60 years and after 
relapsing or for patients not fit for intensive chemotherapy [15–19]. On September 
1, 2017, the (FDA) also approved “GO” for adult patients newly diagnosed AML 
with CD33+.
Ulocuplumab (BMS-936564/MDX-1338) may be a monoclonal antibodies agent 
which inhibits the official of the CXC chemokine receptor 4 (CXCR4) to fortify 
relocation from the bone marrow to peripheral blood stromal cell-derived chemokine 
CXC theme ligand 12 (CXCL12). In patients with refractory and relapsed AML, uloc-
uplumab in combination with mitoxantrone, etoposide and cytarabine driven to CR 
with partial recovery of bone marrow cell lines (CRi) in 51% patients studied [20].
The mutations of FLT 3 appear to be free destitute prognosticators in AML. The 
Mutation in FLT3 gene (FMS-like tyrosine kinase-3) occurs in 30% of FLT3-ITD 
and 7% of FLT3-TDK with AML. The FLT3 kinase inhibitors may be divided into 
1st- and 2nd-generation drugs. 1st-generation: sorafenib, sunitinib, estaurtinib, 
midostaurin l, tandutinib, pacritinib; 2nd-generation: gliteritinib, quizartinib, 
crenolamid, ponatinib, JH-IX-179, PLX3397. The mutated FLT3 gene has variable 
affectability according to type of target therapy [21].
Isocitrate dehydrogenase (IDH) takes place in lipid metabolism and the Krebs 
cycle, and it catalyzes the change of isocitrate to α-ketoglutarate. In AML the gene 
mutations IDH1 occur in 11% and IDH2 in 12% of cases. Enasidenib (AG-221/
CC-90007) is the first single-agent selective IDH2 inhibitor to induce the differen-
tiation of leukemic cells and orally well tolerated. AML in patients with refractory 
or relapsed with mutant-IDH2 induced hematologic responses, and have more than 
9 months median survival reported after treatment with Enasidenib [22].
Target Drug Group
CD33 Gemtuzumab ozogamycin, lintuzumab, vadastuximab talirine High molecular mass 
drugs
CD33, CD3 AMG 330
FLT3 1st-generation: sorafenib, midostaurin, lestaurtinib, sunitinib, 
tandutinib, pacritinib




IDH Cenasidenib Cell pathway Inhibitors
BCL2 Navitoclax, venetoclax
Topoisomerase II Vosaroxin
LSD1 ORY-1001, GSK2879552 Epigenetic modulators
HDAC Pabinostat, vorinostat
Table 1. 
Targeted drugs in AML treatment.
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Navitoclax is BCL2 inhibitor by ABT-199 with multiple anti-apoptotic of 
AML. Its antitumor activity is restricted by adverse effects, which is registered by 
the FDA for treating chronic lymphocytic leukemia (CLL) and AML [23].
Vosaroxin could be a topoisomerase II inhibitor which is one of the important 
randomized trials exploring therapeutic options for refractory and relapsed AML to 
date and considered basic for cell survival. Vosaroxin induces DNA destruction and 
is most successful among elderly patients more than 60 years of age with myelodys-
plastic disorder (MDS) or acute myeloid leukemia (AML) [24].
Lysine-specific demethylase 1 (LSD1) is a histone demethylase. LSD1 inhibition 
leads to the inhibition of growth and metastasis of tumor and also regulates the 
differentiation of stem cells and has potential novel treatment in acute myeloid 
leukemia (AML).
Panobinostat (LBH589) induces AML cell apoptosis in vitro by inhibiting the 
expression of repair proteins (e.g., BRCA1, CHK1 and RAD51), increasing the 
efficiency of cytarabine and daunorubicin, and it is promising in t(8;21) AML 
due to the pathological AML1/ETO protein that recruits histone deacetylases and 
in combination with Azacitidine (AZA) doubled the rate of response in high risk 
patients with CMML, MDS or AML not candidate for stem cell transplantation [25].
Vorinostat (suberoylanilidehydroxamic acid [SAHA]) advances cell cycle inhibi-
tion of growth and induces differentiation and cell apoptosis of AML and reported 
favorable overall survival in AML patients with FLT3 ITD mutations [26].
4. Acute lymphoblastic leukemia (ALL)
The classical main treatment for adult acute lymphoblastic leukemia (ALL) 
is chemotherapy drugs and in some patients the transplant of stem cells in adult 
patients has good results. Advance enhancement maybe calls for a diverse approach 
from conventional chemotherapy, such as target drugs with TKI (imatinib) and/or 
immunotherapy.
ALL with Philadelphia chromosome-positive (Ph+) have been noted with 
impressive response to intensive chemotherapy and imatinib [27].
CD20 is a B cell-specific surface antigen on mature B-ALL and precursor B-ALL, 
as well as in lymphoblastic lymphoma, would manage the probability of rituximab 
response. The introduction of target therapy (rituximab) in combination with che-
motherapy (Hyper-CVAD) (rituximab with hyperfractionated cyclophosphamide, 
doxorubicin, vincristine and dexamethasone) in lymphoma or leukemia, reported 
complete remission rate of 90% with minimal toxicity [28, 29].
Acute lymphoblastic leukemia blast cells express specific antigens for CD22 in 
90% of patients and have amazing clinical action indeed among intensely before 
treatment of elderly B-ALL patients and refractory and relapsed B-ALL patients 
after treatment with inotuzumab ozogamicin. Combination of inotuzumab 
ozogamicin with other treatments after chemotherapy may too possibly improve 
clinical outcomes [30].
Blinatumomab: is a CD3 and CD19-directed, to activate a B-cell specific 
inflammatory and cytolytic response. In 2006 FDA approved Blinatumomab 
for refractory and relapsed ALL [31]. Blinatumomab activates endogenous T 
cells by connecting CD19 on benign and malignant B cells with CD3 in the T-cell 
receptor complex in combination with chemotherapy or as single agents, in pre-
clinical and clinical settings have produced varying response to induce tumor 
cell lysis via complement-dependent cytotoxicity or with antibody, induce cell 
death [32, 33].
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5. Chronic myeloid (Myelogenous) leukemia (CML)
Chronic Myelogenous Leukemia (CML) is a clonal myeloproliferative disorder 
characterized by the increased and unregulated growth of myeloid cells due to 
translocation between long arms of chromosomes 9 and 22t (9;22) that gener-
ates tyrosine kinase BCR-ABL1 [34]. CML classified into 3 phases; chronic stable 
phase (CP) which the myeloid cell series is expanded but cellular differentiation 
is maintained and effortlessly controlled with treatment for a period that can last 
for 36–60 months but the accelerated phase (AP) can lasts for less than 12 months. 
Blast phase (BP) are still poorly understood, characterized by rapid expansion of 
myeloid or lymphoid with presence of more than 20% blast cells in the peripheral 
blood or bone marrow resulting in manifestation of ALL or AML and death in short 
period within 4–6 months [35].
Chronic myeloid (Myelogenous) leukemia treatment progressed significantly 
through the advancement of tyrosine kinase inhibitors (TKIs), particularly the 
presentation of imatinib into the clinical use. Imatinib is the drug of choice of the 
first generation in the chronic phase of CML and considered the golden standard 
target therapy in CML. The second generations also currently available for clinical 
use include nilotinib, dasatinib, bosutinib and ponatinib.
To maintain patients in remission and prevent progression of disease into 
accelerated and blast phases are the main treatment goals of chronic myeloid 
leukemias and keep the patients free of complications and with minimal drug 
related toxicity.
Target therapy with TKIs and allogenic bone marrow transplantation, play 
important role in improvement curative percentage of CML patients.
5.1 Imatinib (Gleevec)
Imatinib mesylate (IM), a phenylaminopyrimidine TKI that is the first drug 
of its class characterized by BCR-ABL TKI has excellent changes in the strategy 
of treatment of CML in the last 20 years. In May 2001, FDA has approved ima-
tinib for the treatment of CML patients. Arthralgia, myalgia, nausea, and fluid 
retention are the common side effects in imatinib. About 97% complete hemato-
logic response and 83% cytogenetic response was documented after many years 
of regular follow up of CML patients received imatinib [36, 37]. Patients with 
hematological or cytogenetic resistance to standard dosage of imatinib (400 mg) 
were begun with tall dosage (600–800 mg). Some of patients are unlikely to be 
overcome by high doses due to some specific mutations, in these cases alterna-
tive target therapy should be considered for patients fails or with suboptimal 
response [38].
5.2 Dasatinib (Sprycel)
Dasatinib is approved in 2006 as a kinase inhibitor of thiazole carboximide 
agent and molecular formula C22H26CIN7O2S.H2O with highly powerful dual Abl/Src 
kinase inhibitor against most imatinib-resistant mutants. Dasatinib considering the 
excellent treatment option for CML cases in chronic phase and other CML phases 
who develop resistance or fails response to imatinib and for cases with Ph+ALL 
[39]. Dasatinib is more than 300 times as powerful as imatinib in restraining 
unmutated BCR-ABL transcripts in vitro. The incidence of resistance to dasatinib is 
less than other TKI and the disease progression may be reduced among CML cases 
treated with dasatinib [40].
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5.3 Nilotinib (Tasigna)
Nilotinib is a small molecule tyrosine kinase inhibitor in the form of hydrochlo-
ride monohydrate salt and is 20–30 times as potent as imatinib and can be replaced 
instead of imatinib. In 2007 nilotinib approved by (FDA) for utilize as a particular 
treatment for Philadelphia chromosome-positive CML (Ph+CML). Nilotinib was 
statistically superior in both complete cytogenetic response (CCyR) and major 
molecular response (MMR) (p < 0.001) [41].
5.4 Bosutinib (Bosulif )
FDA approved bosutinib in September 2012, for adult patients with all phases of 
chronic myeloid leukemia confirmed positive BCR-ABL. Bosutinib is an oral double 
ABL/SRC kinase inhibitor that is dynamic against numerous BCR-ABL transforma-
tions related with imatinib resistance. Bosutinib had the lowest rates of severe side 
effects, except for diarrhea. In especially, severe cardiovascular side effects were 
significantly less common in the bosutinib. They experience not complicated to 
develop blast crisis and progress to accelerated phase in 4% of cases. The overall 
survival at 2 years were 97% [42].
The suggested dosage of bosutinib is 500 mg oral daily dose with nourishment. 
The treatment will be proceeded concurring to plan take after up until progression 
of disease or intolerance of drug.
5.5 Ponatinib (Iclusig)
Ponatinib is approved in December 2012 by the US-FDA as a third generation 
TKI. Ponatinib is indicated for all phases of CML patients develop resistant to nilo-
tinib or dasatinib or not tolerate to nilotinib or dasatinib and for ALL patients with 
Philadelphia chromosome positive and resistant to imatinib, dasatinib or nilotinib.
Patients with severely leukocytosis and patients with monocytosis, are less 
response to tyrosine kinase inhibitors, and have a higher risk of transformation to 
accelerated and blast phase [43]. The dose of ponatinib recommended daily is 45 mg 
with modification according to side effects. The recommendations for treatment of 
CML according to European LeukemiaNet summarized in Table 2.
5.6 Monitoring therapeutic response in CML
The target treatment checking can be performing concurring to inquire about 
laboratory recommendations for scoring molecular response by utilizing either 
a cytogenetic or molecular tests, or both, depending on the open facilities. The 
molecular response to TKI treatment of patients with CML is exceptionally impera-
tive component of CML management with standard take after up each 3 months 
agreeing to ELN guidelines to realize early molecular response playing an impera-
tive part in helpful decision making (Table 3) [45].
The TKI response is the foremost vital prognostic figure. The forecast for CML 
patients in accelerated and blast phases (AP and BP) is less than that seen in chronic 
stage (CP). The treatment responses are characterized as optimal, suboptimal or 
failure. Complete remission accomplished with optimal response which is the most 
excellent result comparable with that of the common populace. Failure implies 
that the understanding ought to get a distinctive treatment to restrain the chance 
of progression of disease and death [46]. Fractional abatement or the problematic 
response is the intermediate zone between optimal response and failure and usually 
considered as “warning” for moving to moment line TKI Table 3.
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6. Chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia (chronic lymphoid leukemia CLL), is a heteroge-
neous disease characterized by the proliferation of functionally incompetent in the 
peripheral blood, bone marrow, spleen and lymph nodes. CLL is a disease of adult 
the elder age group as with a median onset at initial diagnosis of 70 and 75 years old 
and the male to female ratio 2:1 [47].
6.1 Treatment of chronic lymphoyctic leukemia
The CLL disease extent and prognosis according to Rai and Binet staging 
systems. Early stages (0, I, II) and symptomatic patient keep for observation and 
First line Imatinib (400 mg daily) or nilotinib (300 mg twice daily) or dasatinib (100 mg 
daily)
HLA type patients and siblings only in case of baseline warnings (high risk, 
major route CCA/Ph+)
2nd line, intolerance to 
the first TKI
Anyone of the other TKIs approved first line (imatinib 400 mg twice daily, 
nilotinib 400 mg twice daily, dasatinib (70 mg twice daily)
Second line, failure of 
imatinib first line
Dasatinib or nilotinib or bosutinib 500 mg daily or ponatinib (45 mg daily)
HLA type patients and siblings
2nd line, failure of 
nilotinib first line
Bosutinib or dasatinib or ponatinib; search for an unrelated stem cell donor; 
consider AlloSCT and prepare HLA type patients and siblings
2nd line, dasatinib failure 
as first line
Bosutinib or Nilotinib or ponatinib
HLA type patients and siblings; search for an unrelated stem cell donor; 
consider AlloSCT
3rd line, intolerance or 
failure to 2 TKIs
Anyone of the remaining TKIs; alloSCT recommended in all eligible patients
Any line, T315I mutation Ponatinib/omacitaxine; consider AlloSCT and search for an unrelated stem cell 
donor
CCA/Ph+; clonal chromosome abnormalities in Ph+ cells, alloSCT; allogenic stem cell transplantation.
Table 2. 
Target therapy recommendations for chronic myeloid leukemia modified of Abdul Hamid et al. [34].
Complete hematological response (CHR): complete blood counts normalization and spleen return to 
normal with disappearance of chronic myeloid leukemia (CML) manifestations
Complete cytogenetic response (CCyR): absence of Philadelphia chromosome (Ph) in 20 of 20 bone 
marrow metaphases by karyotyping.
Major cytogenetic response (MCyR): presence of Philadelphia chromosome in 0–35% of 20 metaphases.
Molecular response: by follow up of quantitative real time PCR (qRT-PCR) analysis, the BCR-ABL1/control 
gene transcript ratio is determined using the International Scale (IS) standardized baseline. ≥3log10 reduction 
in BCR-ABL1 transcripts (≤0.10% IS) is major molecular response (MMR).
Optimal response: complete hematological response (CHR) and ≤65% Ph+ metaphases at 3 months of 
imatinib therapy, ≤35% Ph+ metaphases at 6 months, CCyR at 12 months and MMR at 18 months.
Suboptimal response: There is no fulfilling criteria for either optimal response or failure. The suboptimal 
response according to ELN recommendations implies that the long term benefits of imatinib are doubtful.
Failure: There is no complete hematological response at 3 months of imatinib therapy, >95% Ph+ metaphases 
at 6 months, >35% Ph+ metaphases at 12 months and no MMR at 18 months. Absence of CHR, BCR-ABL1 
mutations, clonal cytogenetic evolution, define failure at any time during treatment.
Table 3. 
Criteria of therapeutic response [44].
Advances in Hematologic Malignancies
8
regular follow up without treatment. 70% of CLL patients respond to chlorambucil 
monotherapy which may be given orally for stabilization of leukocytosis and symp-
toms. Thrombocytopenia in stage IV stabilized with addition of prednisone.
6.2  Purine nucleoside analogous: (fludarabin, deoxycoformycin, 
2-chlorodeoxy-adenosine)
Are unique drugs that are effective in low grade lymphomas and chronic lym-
phatic leukemia.
Fludarabine is active and useful in patients resist to chlorambucil and in newly 
diagnosed CLL. The alternative use of CVP (Cyclophosphamide, Vincristine and 
Prednisone). In addition fludarabine and cladribine in treatment of CLL, the 
combination of rituximab against CD20 and alemtuzumab against CD52, has an 
acceptable safety profile, and has clinical activity with a short course in patients 
with refractory or relapsed to chemotherapy.
6.3 Ibrutinib (Imbruvica)
Is a small molecule targeted drug that acts as an irreversible burton tyrosine kinase 
inhibitor (BTK) and can be used to treat chronic lymphocytic leukemia (CLL). In 
2013 FDA approved ibrutinib for treatment patients with mantle cell lymphoma and 
in 2013 also approved for CLL and small lymphocytic lymphoma with 17p [48, 49].
6.4 Idelalisib (Zydelig)
Is another targeted drug approved for patients with CLL with CD20 positive 
in combination with rituximab or ofatumumab. It blocks a kinase protein called 
PI3K. FDA in July 28, 2014, has approved idelalisib 150 mg tablets for the treatment of 
B-CLL. Idelalisib has been appeared to assist treat CLL after other medications have been 
attempted and is indicated in combination with rituximab for patients with relapsed 
chronic lymphocytic leukemia (CLL) and significantly reported excellent response rate, 
overall survival and progressed progression-free survival (Tables 4 and 5) [50, 51].
6.5 Venetoclax (Venclexta)
Is a selective drug that targets BCL-2, a protein in CLL cells had a manageable 
response for patients with small lymphocytic lymphoma (SLL) poor prognostic 
and chronic lymphocytic leukemia whose relapsed or refractory to other drugs 





















Novel antibodies and antibody-drug conjugates directed against surface antigens [49].
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7. Non-Hodgkin’s lymphomas (NHL)
Non-Hodgkin’s lymphoma is one of the most common hematologic neoplasms 
and there will be an estimated in USA over 79,000 new cases and over 20,000 
deaths in 2018.
Diffuse large B cell lymphoma (CD20+) is the most common type followed by 
follicular lymphoma and the treatment choices for patients is CHOP protocol with 
or without Rituximab.
7.1 Rituximab
Rituximab is achimeric anti-CD20 human monoclonal IgG1 effective directly 
on the surface receptor found on typical pre-B and mature B cell of non-Hodgkin’s 
lymphoma subtypes, driving to cell cytotoxicity and cell death [53]. It was at first 
utilized in aggressive and very aggressive relapsed or refractory lymphoma and 
demonstrated safety with disease regression and free survival [54].
Major toxicities patients with NHL include infusion-related fever chills, 
fatigue, pruritus, nausea, and vomiting, angioedema, headache, hypotension, 
bronchospasm, urticaria during the first infusion. Rituximab was approved in 
November 1997 for medical use of refractory or relapsed lymphoma (B-cell). 
Rituximab play excellent role in combination with chemotherapy and represents 
a paradigm shift in treatment of lymphomas and improve the outcome for all 
CD20+ NHL and CLL [55].
7.2 Radioimmunotherapy
Radioimmunotherapy (RIT) is a safe and effective treatment option that 
combines the advantages of radiotherapy and immunotherapy and advance the 
adequacy of anti-CD20 target therapy by combining the antibody with a radiocon-
jugate, yttrium-90 without risk of secondary malignancies.
7.2.1 Ibritumomab tiuxetan
Is a monoclonal antibody of IgG1 kappa with name (Zevalin) and the first 
radiopharmaceuticals to be approved for patients with NHL of B lymphocytes 
CD20 molecules. Ibritumomab linking to the metal chelator tiuxetan, a monoclonal 
antibody (111In Zevalin™, Biogen Idec) stable binding of indium-111 (111In) for 
radionucleotide tumor possible with 90Y ibritumomab tiuxetan [56].
Mechanism Drug Target





















Novel antibodies directed against immune checkpoint proteins and novel small molecule inhibitors [49].
Advances in Hematologic Malignancies
10
FDA in February 2002 approved 90Y ibritumomab tiuxetan for treatment of 
refractory and relapsing indolent follicular lymphoma or transformed lymphoma 
which include lymphoma refractory to rituximab.
The toxicity of ibritumomab tiuxetan is primarily hematologic, which is both 
transient and reversible. The common side effects, nausea, vomiting, drug interac-
tions, diarrhea, cough and dizziness.
7.2.2 Tositumomab iodine I 131
Is a CD20 radiotherapeutic targets for treatment of lymphoma patients with 
positive CD20 especially cases of indolent low grade lymphoma, transformed lym-
phoma, refractory and relapsed lymphoma and lymphoma refractory to rituximab.
The therapeutic administration protocol contain two separate products of tosi-
tumomab and iodine I131 tositumomab which will be given in two different steps 
include dosimetric dose and therapeutic dose separated by 10 days interval.
A relapsed, refractory, or transformed indolent low grade lymphoma overall 
response (OR) rates have ranged from approximately 60–80% and CR rates have 
ranged from about 20–40% and a median duration of response of 2 years [57].
Tositumomab toxicities include severe and prolonged thrombocytopenia and 
neutropenia as well as increase risk of developing other diseases include hypothy-
roidism, myelodysplasia, acute leukemia.
In June 2003, Tositumomab approved by FDA for treatment of CD20+ follicular lym-
phoma, that was relapsed following chemotherapy or lymphomas refractory to rituximab.
7.3 Denileukin diftitox
Denileukin diftitox (Ontak) is a fusion protein (interleukin 2 and diphtheria 
toxin) approved by FDA in October 16, 2008, for use as an antineoplastic agent 
to treat pretreated patients with CD25 positive cutaneous T cell lymphomas that 
express IL-2 receptors. A phase III clinical trial, had good response and significant 
improvements in self-rated overall QOL [58].
Denileukin diftitox is available in solution in 2 mL single use vials of 150 μg/mL 
(300 mcg in 2 mL) under the brand name Ontak. The typical dose of intravenous 
infusion is 9 or 18 mcg/kg/day given for 8 courses every 3 weeks.
Epratuzumab is an antihuman CD22 IgG1 antibody that targets CD22 antigen, 
found on the surface of B-lymphocytes antigen, CD22 [59, 60]. This drug, either in 
single administration or in combination with rituximab, created promising out-
comes with complete remission [CR] and an ORR of 67% [49].
7.4 Ofatumumab
In August 2009, ofatumumab was approved as a high-affinity IgG1 mAb that binds 
to a membrane-proximal epitope of the CD20 molecule of the B cell with potential 
anti-neoplastic activity triggering and exhibited greater induction of complement-
dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity 
(ADCC) of B cells over expressing CD20 when compared with rituximab [61].
7.5 Obinutuzumab
Is a unique monoclonal antibody, designed to attach to CD20 antigen expressed 
on the surface of pre-B- and mature B-lymphocytes of malignant lymphoma and 
for maintenance treatment of patients previously untreated low grade lymphoma 
especially follicular type resulted in significant free survival. The post-translational 
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glycoengineering process used in the development of this agent, add to its higher 
binding affinity for human FcγRIII receptors on immune effector cells and the 
mAbs to novel targets are being developed with ADCC in mind [62].
7.6 Brentuximab vedotin
An anti-CD30 antibody-drug conjugate and demonstrated significant clinical 
activity in patients with CD30+ malignancies, including Reed Sternberg cells in 
classical HL and anaplastic large cell lymphoma (ALCL) (Tables 4 and 5).
8. Multiple myeloma
Multiple myeloma (MM) is a blood cancer that remains serious disease and it 
cannot usually be cured because most patients relapse after treatment or become 
refractory to the treatments.
Novel agents are as of now in advancement for the management of refractory or 
relapsed multiple myeloma, counting immunomodulatory drugs, monoclonal anti-
bodies, proteasome inhibitors, cell signaling focused on treatments, and procedures 
focusing on the tumor infiltration or metastasis.
Proteasome inhibitors such as bortezomib target therapy of multiple myeloma 
the ubiquitin pathway, coming about in cytotoxic damage due to disturbance of 
protein corruption in myeloma cells. The immunomodulatory agents, thalidomide, 
lenalidomide, and pomalidomide, are a novel of class of oral target agents impact on 
myeloma cells through a few components counting coordinate cytotoxicity, antian-
giogenic impacts, and antitumor immunity activation (Figure 1).
8.1 Proteasome inhibitors
The proteasome is a gigantic highly sophisticated protease complex that degrades 
unneeded or damaged proteins by proteolysis. As such, the proteasome plays an 
important role in critical cellular processes including proliferation, differentiation, 
cell cycle progression and survival DNA repair, angiogenesis and apoptosis [63]. 
Three proteasome inhibitors, carfilzomib, bortezomib and ixazomib are approved 
by FDA and oprozomib and other agents are in the clinical trials late stages.
Figure 1. 
History of multiple myeloma treatment.
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8.2 Bortezomib
Bortezomib (Velcade) is the first proteasome inhibitor approved by FDA in May 
2003. A trial phase I explored bortezomib for its tolerance and safety in multiple 
myeloma, lymphoma, leukemia and lung cancers [64]. Bortezomib showed safely tol-
erability with few side effects such as general weakness, fever, fatigue, decreased sen-
sation and paresthesia, nausea, vomiting and thrombocytopenia. Amazing response 
rate (35%) and response duration reaching to more than 1 year in intensely pretreated 
multiple myeloma patients were reported in the SUMMIT phase II trial [65].
8.3 Carfilzomib
Carfilzomib is a new intravenous agent approved by FDA in 2018 for multiple 
myeloma of proteasome inhibitors like bortezomib. It should be given with dexa-
methasone or with dexamethasone and lenalidomide in refractory or relapsed 
multiple myeloma. In differentiate carfilzomib with bortezomib, appears a bet-
ter selectivity to the proteasome, covering more of the proteolytic subunits. The 
common side effects are mild to moderate fever, cytopenia, diarrhea, headache and 
swelling in hands and feet [66].
8.4 Ixazomib
FDA approved ixazomib in 2015 as the first an oral proteasome inhibitor. 
Ixazomib used in the same time with dexamethasone and lenalidomide for the 
treatment patients with refractory or relapsed multiple myeloma [67].
8.5 Immunomodulatory drugs (IMiDs)
The presentation of immunomodulatory drugs (IMiDs), assist progressed 
long-term survival of patients with multiple myeloma. Thalidomide and its deriva-
tives, lenalidomide and pomalidomide possess pleiotropic anti-myeloma properties 
including immune-modulation, anti-angiogenic, anti-inflammatory and anti-
proliferative effects.
8.6 Monoclonal antibodies (MoAbs)
Presentation of the primary mAb different therapy of multiple myeloma started 
a modern time in multiple myeloma therapy. Daratumumab, focusing on CD38 
as an exceedingly and constantly expressed surface antigen of myeloma, is the 
primary counter acting agent that was approved by the FDA for the treatment of 
newly-diagnosed multiple myeloma and also for refractory and relapsed myeloma 
patients [68]. Elotuzumab, targeting signaling lymphocytic activation molecule F7 
(SLAMF7), has been endorsed in combination with lenalidomide and dexametha-
sone for therapy of myeloma patients in relapse or refractory to treatment [69].
8.7 Histone-deacetylase (HDAC) inhibitors
An assortment of epigenetic changes together with hereditary changes is basic 
for malignant growth and proliferation. Altering acetylation status of histones is, 
close by DNA methylation, an option to gene alteration and blocks gene transcrip-
tion and inhibits differentiation, providing a rationale for developing HDAC inhibi-
tors. Panobinostat was excessively attempted with different mixes in a few clinical 
stage I/II trials.
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